Enanta Pharmaceuticals (ENTA) Operating Expenses (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Operating Expenses came in at $29.0 million in Q1 2026, down 26.47% YoY from $39.5 million in Q1 2025, and down 2.87% on a QoQ basis from $29.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Operating Expenses (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Operating Expenses data on file, last reported at $29.0 million in Q1 2026.
- Quarterly Operating Expenses fell 26.47% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.6 million (down 22.2% YoY) and the FY2025 annual result came in at $150.7 million, down 20.42% from the prior year.
- Operating Expenses eased to $29.0 million in Q1 2026, from $29.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $57.2 million in Q1 2023 to a low of $29.0 million in Q1 2026.
- A 5-year average of $45.1 million and a median of $47.4 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses advanced 8.91% — and 2026, when it declined 26.47%.
- Tracing ENTA's Operating Expenses over 5 years: stood at $53.6 million in 2022, then fell by 1.32% to $52.9 million in 2023, then retreated by 23.42% to $40.5 million in 2024, then dropped by 26.26% to $29.9 million in 2025, then declined by 2.87% to $29.0 million in 2026.
- The last three Operating Expenses figures came in at $29.0 million (Q1 2026), $29.9 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 31.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.60 Mn |
| Mar 31, 2026 | 29.01 Mn |
| Dec 31, 2025 | 29.87 Mn |
| Sep 30, 2025 | 33.51 Mn |
| Jun 30, 2025 | 37.21 Mn |
| Mar 31, 2025 | 39.45 Mn |
| Dec 31, 2024 | 40.50 Mn |
| Sep 30, 2024 | 44.46 Mn |
| Jun 30, 2024 | 42.16 Mn |
| Mar 31, 2024 | 49.82 Mn |
| Dec 31, 2023 | 52.89 Mn |
| Sep 30, 2023 | 49.96 Mn |
| Jun 30, 2023 | 55.61 Mn |
| Mar 31, 2023 | 57.25 Mn |
| Dec 31, 2022 | 53.60 Mn |
| Sep 30, 2022 | 47.37 Mn |
| Jun 30, 2022 | 52.02 Mn |
| Mar 31, 2022 | 52.56 Mn |
| Dec 31, 2021 | 58.06 Mn |
| Sep 30, 2021 | 57.30 Mn |